The abstract reports that ailanthone exhibits BBB permeability and specifically targets tumor areas, but provides no mechanistic explanation for this selective targeting. Understanding this mechanism is crucial for developing brain-targeted therapeutics and could reveal new approaches for drug delivery across the BBB. Gap type: unexplained_observation Source paper: Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-α/LINC01956/FUS/β-catenin signaling pathway in glioblastoma. (None, None, PMID:39639311)
Landscape Summary: How does ailanthone selectively cross the blood-brain barrier and target glioma tissue? is a 0.8 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How does ailanthone selectively cross the blood-brain barrier and target glioma tissue? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: